Rapidly progressive pulmonary fibrosis in a patient treated with danazol for idiopathic thrombocytopenic purpura.
The case of a patient that developed pulmonary fibrosis two months after initiation of danazol for treatment of idiopathic thrombocytopenic purpura is described. Bilateral pneumothoraxes and pneumomediastinum complicated the rapidly fatal pulmonary fibrosis. An association between danazol therapy and the development of pulmonary fibrosis is suspected. There is only one other case report with this connection in the literature.
Pakhale
Smita
S
Department of Respirology, Toronto General Hospital, Toronto, Onrtario. Smita.pakhale@utoronto.ca
Moltyaner
Yuri
Y
Chamberlain
Dean
D
Lazar
Neil
N
D000368:Aged; D003613:Danazol / Q000009:adverse effects*; D004965:Estrogen Antagonists / Q000009:adverse effects*; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D008168:Lung / Q000000981:diagnostic imaging / Q000473:pathology; D011030:Pneumothorax / Q000139:chemically induced / Q000175:diagnosis / Q000628:therapy; D011658:Pulmonary Fibrosis / Q000139:chemically induced* / Q000175:diagnosis / Q000628:therapy; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000150:complications / Q000188:drug therapy*; D011859:Radiography
D004965:Estrogen Antagonists; D003613:Danazol